April 17, 2024
Press Releases for Artiva Biotherapeutics
February 22, 2024
Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis
November 8, 2023
Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023 BioTech Breakthrough Awards Program
August 16, 2023
Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis
May 25, 2023
Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
April 26, 2023
Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
January 31, 2023
Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101
November 10, 2022
Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting
November 3, 2022
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101
November 3, 2022